Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
作者： Ruben Mujica-Mota , Jo Varley-Campbell , Irina Tikhonova , Chris Cooper , Ed Griffin
DOI: 10.3310/HTA22490
关键词: Internal medicine 、 Cost effectiveness 、 Cost-effectiveness analysis 、 Health technology 、 Sunitinib 、 Cost–benefit analysis 、 Quality-adjusted life year 、 Everolimus 、 MEDLINE 、 Medicine 、 Oncology
摘要: Funding for this study was provided by the Health Technology Assessment programme of National Institute Research.
sci-hub.st 参考文章(170)
G. Scarpelli, V. Ramundo, D. Ferone, P. Ferolla, G. Angeletti, A. Faggiano, L. M. Camera, F. Grimaldi, A. Colao, M. C. Bellucci, R. Severino, G. Lombardi, Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses Journal of Endocrinological Investigation. ,vol. 35, pp. 326- 331 ,(2011) , 10.3275/7869
Henia Balter, Trindade Victoria, Terán Mariella, Gaudiano Javier, Ferrando Rodolfo, Paolino Andrea, Rodriguez Graciela, Hermida Juan, De Marco Eugenia, Oliver Patricia, 177 Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay Current Radiopharmaceuticals. ,vol. 9, pp. 85- 93 ,(2015) , 10.2174/1874471008666150313112620
Phillip G. Claringbold, J. Harvey Turner, Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy Neuroendocrinology. ,vol. 103, pp. 432- 439 ,(2016) , 10.1159/000434723
Stefano Severi, Maddalena Sansovini, Annarita Ianniello, Lisa Bodei, Silvia Nicolini, Toni Ibrahim, Valentina Di Iorio, Vincenzo D’Errico, Paola Caroli, Manuela Monti, Giovanni Paganelli, Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 1955- 1963 ,(2015) , 10.1007/S00259-015-3105-7
Phillip G. Claringbold, J. Harvey Turner, NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study Cancer Biotherapy and Radiopharmaceuticals. ,vol. 30, pp. 261- 269 ,(2015) , 10.1089/CBR.2015.1876
Emilio Bajetta, Laura Catena, Nicola Fazio, Sara Pusceddu, Pamela Biondani, Giusi Blanco, Sergio Ricci, Michele Aieta, Francesca Pucci, Monica Valente, Nadia Bianco, Chiara Maria Mauri, Francesca Spada, Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. ,vol. 120, pp. 2457- 2463 ,(2014) , 10.1002/CNCR.28726
Manal M. Hassan, Alexandria Phan, Donghui Li, Cecile G. Dagohoy, Colleen Leary, James C. Yao, Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study International Journal of Cancer. ,vol. 123, pp. 867- 873 ,(2008) , 10.1002/IJC.23529
Julie Hallet, Calvin How Lim Law, Moises Cukier, Refik Saskin, Ning Liu, Simron Singh, Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes Cancer. ,vol. 121, pp. 589- 597 ,(2015) , 10.1002/CNCR.29099
Jun Yao, Jian-yao Wang, Yi Liu, Bin Wang, Ying-xue Li, Ru Zhang, Li-Sheng Wang, Lei Liu, Retraction Note to: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients Medical Oncology. ,vol. 31, pp. 251- ,(2014) , 10.1007/S12032-015-0661-4
A. Sabet, F. Khalaf, C. J. Yong-Hing, A. Sabet, T. Haslerud, H. Ahmadzadehfar, S. Guhlke, F. Grünwald, H.-J. Biersack, S. Ezziddin, Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin-nuclear Medicine. ,vol. 53, pp. 54- 59 ,(2014) , 10.3413/NUKMED-0614-13-08